Clinician’s Brief spotlights multimodal OA pain management

Clinician’s Brief is spotlighting osteoarthritis pain management again with a sponsored podcast featuring Robin Downing, DVM, a longtime voice in veterinary pain medicine. In “Practical Advice on Managing Osteoarthritis Pain With Dr. Downing,” Downing discusses how practices can move beyond a narrow, drug-only view of arthritis care and instead build more complete pain-control strategies while helping pet parents recognize subtle signs of chronic discomfort. (cliniciansbrief.com)

That message lands in a veterinary market that has changed meaningfully over the past several years. The 2022 AAHA Pain Management Guidelines for Dogs and Cats emphasized that pain management should be proactive, individualized, and multimodal, with chronic pain care extending well beyond episodic NSAID prescribing. The guidance also stresses that clinical signs and behavior often matter more than imaging alone when assessing pain severity, and that burden of care for the pet parent should factor into treatment planning. (aaha.org)

Clinician’s Brief’s broader osteoarthritis coverage shows the same editorial direction. Its orthopedics section now groups Downing’s episode alongside newer mobility-focused content, including a December 2025 podcast with rehabilitation specialist Matthew Brunke and additional sponsored material on nonpharmacologic OA therapies. In that Brunke discussion, the emphasis was explicitly on management strategies beyond medications and supplements, with mobility framed as a major quality-of-life issue in both dogs and cats. Brunke also called attention to a commonly missed point in small animal practice: cats are often underrecognized in mobility conversations even though obesity and aging make primary osteoarthritis a frequent concern. Together, those pieces point to a consistent industry theme: OA management is increasingly being discussed as a combination of medication, nutrition, exercise, rehab, and home-environment support, rather than a single-product decision. (cliniciansbrief.com)

The pharmacology backdrop matters here. Zoetis’ anti-NGF monoclonal antibody Librela was approved by the FDA in May 2023 for control of pain associated with osteoarthritis in dogs, adding a new mechanism to the canine pain toolkit. In March 2025, Zoetis said a head-to-head study found Librela provided pain relief equivalent to meloxicam, supporting the idea that biologics and NSAIDs may both have first-line roles in some patients. At the same time, FDA safety-related labeling changes published February 18, 2025, added stronger language around post-approval adverse event communication and instructed veterinarians to provide a client information sheet before each injection. (news.zoetis.com)

That tension, expanding treatment choice paired with more active safety monitoring, is likely why practical discussions such as Downing’s continue to resonate. The available evidence and guidance support multimodal care, but they also reinforce the need for patient selection, follow-up, and clear communication. AAHA’s guidance highlights weight control, rehab, and environmental support as important components of chronic pain care, while Clinician’s Brief’s related OA coverage underscores nutrition and nonpharmacologic therapies as useful complements to drug therapy. Brunke’s mobility-focused comments sharpen that point by tying joint health directly to day-to-day function and by reminding clinicians that indoor, overweight, aging cats may show arthritis in quieter ways than dogs do. (aaha.org)

Expert commentary in the space has been consistent on one point: osteoarthritis pain is rarely best managed with a one-note plan. In prior veterinary trade coverage, Downing has argued that multimodal treatment components work synergistically, and other Clinician’s Brief contributors have recently echoed that view, emphasizing body condition management, exercise, and cautious use of adjunctive analgesics alongside core therapies. The Brunke podcast extends that same practical framing into mobility medicine, with a focus on preserving function, supporting recovery, and looking beyond pills alone. While the new podcast page itself is promotional and light on transcript-level detail, it fits squarely within that broader clinical consensus. (dvm360.com)

Why it matters: For veterinary professionals, this isn’t just another sponsored content item. It reflects how OA care is being operationalized in practice: more options, more monitoring, more need for team-based follow-up, and more pressure to explain tradeoffs clearly to the pet parent. As clinics weigh NSAIDs, adjunctive drugs, diets, supplements, rehab, and biologics, the differentiator may be less about any one product and more about building a repeatable protocol for assessment, shared decision-making, and reassessment over time. The added mobility-focused coverage also broadens the clinical lens, especially for cats, where obesity, aging, and subtle behavior changes can make osteoarthritis easy to miss unless teams are actively looking for it. (jaaha.kglmeridian.com)

What to watch: Watch for more clinic-facing education on sequencing and combining OA therapies, continued scrutiny of post-market safety data for newer agents, and further efforts by media and industry groups to standardize how veterinarians talk with pet parents about chronic pain, function, and quality of life. Also expect more emphasis on practical mobility support strategies, including rehab and weight management, and on improving recognition of feline osteoarthritis in general practice. (fda.gov)